Using cell therapy as a treatment for liver cancer
Group leader: Dr Stuart Curbishley
Stuart’s research group are interested in translating novel cell therapy based cancer vaccines into the clinic. The group are based in the IBR but work extensively in the MHRA licensed Advanced Therapies Facility where they manufacture cell based vaccines in accordance with Good Manufacturing Practice (GMP). They are currently carrying out the ImmunoTACE trial, a dendritic cell vaccine delivered in combination with standard of care for patients with liver cancer. Stuart’s group are also interested in monitoring changes in the immune system of patients undergoing treatment for cancer.
Our research group
Miss Miroslava Blahova, Research Associate
Dr Manita Mehmi, Research Technician
Dr Ankit Rao, Clinical Lecturer
Khan MW, Curbishley SM, Chen HC, Thomas AD, Pircher H, Mavilio D, Steven NM, Eberl M and Moser B (2014) Expanded Human Blood-Derived γδT Cells Display Potent Antigen-Presentation Functions. Front Immunol 5:344
Ward ST, Li KK, Hepburn E, Weston CJ, Curbishley SM, Reynolds GM, Hejmadi RK, Bicknell R, Eksteen B, Ismail T, Rot A and Adams DH (2015) The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br J Cancer 112(2):319–28
Ward ST, Li KK and Curbishley SM (2014) A method for conducting suppression assays using small numbers of tissue-isolated regulatory T cells. MethodsX. 1: 168–174.